Drug Development Pipeline
Gallium is a molecule, nearly identical to iron, that disrupts iron-dependent biological processes and has been shown to kill antibiotic-resistant strains of Pseudomonas aeruginosa in laboratory research. Gallium has already been approved by the FDA for intravenous use in people. It is currently being studied for its effectiveness in treating infections in people with CF.
A phase 2 study to test the safety and effectiveness of IV gallium in controlling P. aeruginosa in people with CF has been completed. A phase 1 study to test safety and effectiveness in adults with CF who have nontuberculous mycobacteria (NTM) is currently underway.
This program is sponsored by the Cystic Fibrosis Foundation and is being conducted within the Therapeutics Development Network.
Recent Intravenous Gallium Studies
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More